Amendment to Manufacturing Agreement

EX-10.4 3 c23753exv10w4.htm AMENDMENT TO MANUFACTURING AGREEMENT exv10w4
 

Exhibit 10.4
AMENDMENT TO MANUFACTURING AGREEMENT
The Manufacturing Agreement between Alcon Pharmaceuticals Ltd. (“Alcon”) and Lifecore Biomedical, Inc. dated effective on January 1, 2006, is hereby amended as follows:
1.) In Article 2.06, ALCON’s Minimum Volume is increased to ** of Product during each calendar year beginning in 2009.
2.) The pricing table in Article 3.01 is hereby updated and replaced with the following pricing table:
         
    Price per gram
Year   (USD
2008
   USD **
2009
   USD **
2010
   USD **
2011
   USD **
2012
   USD **
2013
   USD **
3.) In Article 7.01, the term of the Agreement is hereby extended through December 31, 2013.
These changes will be effected and become part of the Manufacturing Agreement on February 1, 2008. With the exception of the above modifications, all other provisions of the Manufacturing Agreement remain in full force and effect. Please signify your agreement with the above by signing below and returning this letter to Alcon.
ALCON PHARMACEUTICALS LTD.
                             
By:   /s/ JOANNE BECK     By:   /s/ STEFAN BASLER    
                     
 
  Name:   Joanne Beck           Name:   Stefan Basler    
 
  Title:   General Manager           Title:   Finance Manager    
 
  Date:   January 25, 2008           Date:   January 25, 2008    
         
LIFECORE BIOMEDICAL, INC.
 		    
By:   /s/ LARRY HIEBERT      
  Name:   Larry Hiebert     
  Title:   Vice President and General Manager of the HD Division     
  Date:   January 23, 2008     
 

 

 

 
**   The appearance of a double asterisk denotes confidential information that has been omitted from the exhibit and filed separately, accompanied by a confidential treatment request, with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934.

-2-